narmac - Just thinking about the waterfall effect that would have to occur in you scenario. $7Cdn or $5.40US in February and doing a financing on Nasdaq mid year would mean we had passed the trial with some reasonable numbers. For a drug with 12 million potential customers in the top 8 markets alone, we would have to have shown by then to have a positive affect on diabetic cvd, ckd and potentially cognitive function. By mid 2019 the Third Eye loan will have to have been paid off or refinanced as well. To have apabetalone pass a phase III trial and ready to be a mega blockbuster drug by mid 2019 we would either be gone in a takeover or the financing required to deal with Third Eye would have changed the dance floor for us long before then.

After having said nothing about cognitive function for longer than the first 2 years of this trial and then talking about it at every opportunity, IMO something very good could happen long before mid 2019. I just hope the Top Line numbers reach the expectations of the market so the secondary targets get to shine the way they could.

Like yours, this is just my opinion.

tada